Drug release from lipid-based implants: Elucidation of the underlying mass transport mechanisms

被引:62
作者
Guse, C
Koennings, S
Kreye, F
Siepmann, F
Goepferich, A
Siepmann, J [1 ]
机构
[1] Free Univ Berlin, Coll Pharm, D-12169 Berlin, Germany
[2] Univ Regensburg, Coll Pharm, D-93040 Regensburg, Germany
[3] Univ Lille, Coll Pharm, F-59006 Lille, France
关键词
lipid; implant; controlled release; release mechanism; mathematical modeling;
D O I
10.1016/j.ijpharm.2005.08.030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to better understand the mass transport mechanisms involved in the control of drug release from lipid-based implants. Different types of triglyceride-based cylinders were prepared by compression. Glycerol-trilaurate, -trimyristate, -tripalmitate and -tristearate were used as model lipids, lysozyme and pyranine as model drugs. The effects of several formulation and processing parameters on the resulting drug release kinetics in phosphate buffer pH 7.4 were studied and the obtained results analyzed using Fick's second law of diffusion. Interestingly, lysozyme release from implants prepared by compression of a lyophilized emulsion (containing dissolved drug and lipid) was found to be purely diffusion-controlled, irrespective of the type of triglyceride. In contrast, the dominating release mechanism depended on the type of lipid in the case of pyranineloaded implants prepared by compression of a lyophilized lipid-drug solution: with glycerol-trilaurate and -tristearate the systems were found to be purely diffusion-controlled, whereas also other mass transport phenomena are of importance in glycerol-trimyristate and -tripalmitate-based devices. Similarly, changes in the size of the compressed lipid-drug particles, drug loading and compression force significantly affected the underlying release mechanisms. The addition of a drug-free, poly(lactic-co-glycolic acid) (PLGA)-based coating around the implants delayed the onset of pyranine release for about 20 days. Interestingly, the subsequent drug release was purely diffusion-controlled, irrespective of the type of triglyceride. Also the addition of different amounts (and particle size fractions) of saccharose to pyranine-loaded implants led to purely diffusion-controlled drug release. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 20 条
[1]  
Crank J., 1979, MATH DIFFUSION
[2]   HYDROLYTIC DEGRADATION OF DEVICES BASED ON POLY(DL-LACTIC ACID) SIZE-DEPENDENCE [J].
GRIZZI, I ;
GARREAU, H ;
LI, S ;
VERT, M .
BIOMATERIALS, 1995, 16 (04) :305-311
[3]   Programmable implants - From pulsatile to controlled release [J].
Guse, C. ;
Koennings, S. ;
Blunk, T. ;
Siepmann, J. ;
Goepferich, A. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 314 (02) :161-169
[4]   THE RELEASE OF MACROMOLECULES FROM FATTY-ACID MATRICES - COMPLETE FACTORIAL STUDY OF FACTORS AFFECTING RELEASE [J].
KAEWVICHIT, S ;
TUCKER, IG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (09) :708-713
[5]   Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants [J].
Kang, JC ;
Schwendeman, SP .
BIOMATERIALS, 2002, 23 (01) :239-245
[6]  
Lu L, 1999, J BIOMED MATER RES, V46, P236, DOI 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO
[7]  
2-F
[8]   Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma:: A randomized phase II trial [J].
Menei, P ;
Capelle, L ;
Guyotat, J ;
Fuentes, S ;
Assaker, R ;
Bataille, B ;
François, P ;
Dorwling-Carter, D ;
Paquis, P ;
Bauchet, L ;
Parker, F ;
Sabatier, J ;
Faisant, N ;
Benoit, JP .
NEUROSURGERY, 2005, 56 (02) :242-247
[9]   Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma - A phase I study [J].
Menei, P ;
Jadaud, E ;
Faisant, N ;
Boisdron-Celle, M ;
Michalak, S ;
Fournier, D ;
Delhaye, M ;
Benoit, JP .
CANCER, 2004, 100 (02) :405-410
[10]  
Menei P, 1999, CANCER, V86, P325, DOI 10.1002/(SICI)1097-0142(19990715)86:2<325::AID-CNCR17>3.3.CO